Cure My Disease

Don't miss your cure!

 Log in / Sign up

Electric fields could prime immune system against lung cancer

NCT ID NCT05764954

Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether a device that delivers electric fields (TTFields) to lung tumors is safe and practical when used for 3 weeks before surgery. The study includes 12 people with early-stage lung adenocarcinoma. Researchers also want to see if this treatment can boost the body's immune response against the cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tumor-Treating Fields (TTFields) via the NovoTTF-200T System
What this could lead to
If it works, this could point toward a new way to help the immune system fight lung cancer before surgery, potentially improving outcomes.
What could go wrong
This is a very early, small phase 1 trial with only 12 participants, so results may not apply widely. The device must be worn 18 hours daily for 3 weeks, which may be burdensome, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

12 people

The number who actually took part.

Started

Aug 2023

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The participant (or legally acceptable representative \[LAR\], if applicable) provides written informed consent for the study. * The participant is ≥22 years of age on the day of signing informed consent. * The participant has clinical stage 1A2, 1A3 or IB biopsy-proven lung ADC and is eligible for anatomical resection. * The participant has a lung nodule \>1 cm and suspected lung ADC with a plan to undergo biopsy. * The participant with multiple nodules has one nodule that meets the criteria. * The participant has no history of prior malignancy in the chest or has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy. Exclusion Criteria: * Patients receiving therapy for concurrent active malignancy * Patients with a history of cardiac arrhythmias and/or pacemaker use * Patients with lung nodules \<1cm * Patients with lung nodules that are pure ground glass opacities (GGOs) of any size * Patients with lung nodules that are \<50% solid of any size

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adenocarcinoma of lung are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma of Lung lung adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adenocarcinoma of lung

Contacts and locations

Locations

  • Memorial Sloan Kettering Basking Ridge (Consent Only)

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen (Consent Only)

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Monmouth (Consent Only)

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau (Consent Only)

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Suffolk - Commack (Consent Only)

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Westchester (Consent Only)

    Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.